E. Vazquez

发表

Phase II study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung cancer.

J. Reeves, J. Hainsworth, H. Burris, 2010, Clinical lung cancer.

Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer.

J. Hainsworth, J. Bendell, H. Burris, 2010, Clinical advances in hematology & oncology : H&O.

A Phase II Trial of Carboplatin and Weekly Topotecan in the First-Line Treatment of Patients with Extensive Stage Small Cell Lung Cancer

Suzanne F. Jones, J. Hainsworth, H. Burris, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase II randomized crossover study of liposomal doxorubicin versus weekly docetaxel in the first-line treatment of women with metastatic breast cancer.

J. Hainsworth, H. Burris, D. Yardley, 2009, Clinical breast cancer.

Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium.

I. Flinn, J. Hainsworth, H. Burris, 2010, Clinical lymphoma, myeloma & leukemia.

Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first‐line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma

J. Hainsworth, D. Spigel, F. Greco, 2008, Cancer.

SPARC microenvironment signature (SMS) analysis of a phase II trial of neoadjuvant gemcitabine (G), epirubicin (E), and nab-paclitaxel (nab-P) in locally advanced breast cancer (LABC).

H. Rugo, R. Inhorn, D. Yardley, 2010 .

Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC)

J. Hainsworth, H. Burris, D. Yardley, 2008 .

A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood ( 16 years ) low grade glioma e A final report

K. Skullerud, T. Egeland, D. Machin, 2017 .

A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer.

J. Hainsworth, H. Burris, D. Yardley, 2011, Clinical advances in hematology & oncology : H&O.

A phase II trial of dose-dense neoadjuvant gemcitabine, epirubicin, and albumin-bound paclitaxel with pegfilgrastim in the treatment of patients with locally advanced breast cancer.

J. Hainsworth, H. Burris, R. Inhorn, 2010, Clinical breast cancer.

A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer.

J. Hainsworth, D. Yardley, N. Peacock, 2010, Clinical breast cancer.

Preliminary safety results from a multicenter phase II trial of nanoparticle albumin-bound paclitaxel/cyclophosphamide in early stage breast cancer plus trastuzumab in HER-2+ patients (pts).

J. Hainsworth, R. Inhorn, D. Yardley, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

K. Skullerud, T. Egeland, D. Machin, 2017, European journal of cancer.